Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06556810 · ClinicalTrials.gov registry record · Phase 1

IC14 for Treatment of Acute Decompensated Heart Failure

A Phase 1 study of Acute Decompensated Heart Failure, sponsored by Implicit Bioscience.

Active
Registry status
Phase 1
Development phase
10
Enrollment target
2
Study locations

NCT06556810 is a Phase 1 study of Acute Decompensated Heart Failure that is active but no longer recruiting, run by Implicit Bioscience. The registered enrollment target is 10 participants, below the 458-participant average among 12 other Acute Decompensated Heart Failure trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06556810, a Phase 1 study of Acute Decompensated Heart Failure, is active but no longer recruiting, sponsored by Implicit Bioscience.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to learn if drug atibuclimab (IC14) works to treat adults hospitalized with acute decompensated heart failure (ADHF). It will also learn about the safety of IC14. The main questions it aims to answer are: Is the drug IC14 safe in patients with ADHF? What are the IC14 drug levels in the bloodstream after treatment with IC14? What is the impact of IC14 treatment on markers of disease in the bloodstream? What is the impact of IC14 treatment on measures of heart failure? There is no placebo arm in this study. Participants will: Take drug IC14 once via an intravenous infusion After the infusion, be visited in the hospital or visit the clinic 5 times for checkups and tests Answer questions about their medical status via a phone call 3 months after the infusion

Conditions Studied

Acute Decompensated Heart Failure

Interventions

  • DRUG Atibuclimab (IC14)

Study Locations (2)

Virginia

  • University of Virginia - Charlottesville
  • Virginia Commonwealth University - Richmond

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2024-10-17
Est. Completion 2026-01-31
Phase Phase 1

Sponsor

Implicit Bioscience

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06556810

The ClinicalTrials.gov registry entry for NCT06556810 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 458-participant average among 12 other Acute Decompensated Heart Failure trials with a reported enrollment target (98% lower). The listed sponsor is Implicit Bioscience, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Decompensated Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Atibuclimab (IC14) is the first listed.

NCT06556810 reports 2 study locations spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT06556810 about?

NCT06556810 is a clinical study titled "IC14 for Treatment of Acute Decompensated Heart Failure". The goal of this clinical trial is to learn if drug atibuclimab (IC14) works to treat adults hospitalized with acute decompensated heart failure (ADHF). It will also learn about the safety of IC14. The main questions it aims to answer are: Is the drug IC14 safe in patients with ADHF? What are the I...

What is the current status of trial NCT06556810?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-10-17. Estimated completion is 2026-01-31.

What conditions does trial NCT06556810 study?

This clinical trial studies the following conditions: Acute Decompensated Heart Failure.

What interventions are being tested in trial NCT06556810?

The interventions under investigation include: Atibuclimab (IC14) (DRUG).

Who is sponsoring clinical trial NCT06556810?

This trial is sponsored by Implicit Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06556810 being conducted?

This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Decompensated Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Decompensated Heart Failure

All registered trials for this condition

Virginia

All trials with a study site in Virginia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.